Bivalirudin

Bivalirudin binds thrombin at two sites simultaneously: (1) the C-terminus of bivalirudin (D-Phe-Pro-Arg-Pro) binds the catalytic active site, blocking thrombin's protease activity; and (2) the N-terminal dodecapeptide tail binds thrombin's anion-binding exosite-1, which is the fibrinogen recognition site. This bivalent binding creates a tight (though not covalent) complex. Unlike heparin, bivalirudin inhibits clot-bound (fibrin-bound) thrombin in addition to free thrombin, potentially providing superior anticoagulation at sites of active clot.

A unique pharmacological feature: thrombin itself cleaves bivalirudin at the Arg3-Pro4 bond in its active site, progressively restoring thrombin activity. This creates a self-limiting inhibition dynamic with potential for natural drug clearance and predictable reversal. The cleavage product loses the active-site binding arm but retains weak exosite-1 binding. This partial autocleavage contributes to bivalirudin's relatively short anticoagulant duration and reduces rebound thrombosis risk after stopping the infusion.

Bivalirudin is cleared by a combination of renal excretion (~20%) and proteolytic degradation (~80%), with a plasma half-life of ~25 minutes in patients with normal renal function. Dose adjustment is required for reduced renal clearance (GFR 10-30 mL/min: reduce infusion rate to 1 mg/kg/h). Unlike heparin, bivalirudin does not require antithrombin III, is not neutralized by platelet factor 4 (avoiding HIT), and has predictable linear pharmacokinetics without extensive protein binding.

Multiple large RCTs (HORIZONS-AMI, ISAR-REACT 3, BRIGHT) established bivalirudin efficacy and safety in PCI. Compared to unfractionated heparin plus glycoprotein IIb/IIIa inhibitors, bivalirudin reduced major bleeding events by ~40% with similar or slightly higher rates of acute stent thrombosis. Net clinical benefit favored bivalirudin in trials with routine GP IIb/IIIa inhibitor use; modern PCI with radial access and novel P2Y12 inhibitors has made the advantage less pronounced.

HIT is a life-threatening immune thrombocytopenia from heparin-platelet factor 4 antibodies causing thrombosis. In HIT, all heparins are contraindicated. Bivalirudin (and argatroban) are FDA-approved alternatives for anticoagulation in HIT patients requiring PCI or other procedures. Bivalirudin's short half-life is an advantage in HIT, if the patient develops complications, rapid reversal occurs naturally without protamine.

In STEMI treated with primary PCI, HORIZONS-AMI showed bivalirudin reduced net adverse clinical events primarily through major bleeding reduction, with a mortality benefit at 30 days and 3 years. Subsequent meta-analyses in the era of modern antiplatelet therapy and radial access show attenuated benefits but bivalirudin remains guideline-recommended as an acceptable alternative to UFH in high bleeding-risk STEMI.